EU CHMP Backs Extended Libtayo Dosing Schedule

The EMA’s CHMP issued a positive opinion allowing Libtayo 700 mg every six weeks after 12 weeks across EU indications, with an optional 15–30-minute infusion for the 350 mg dose. A final European Commission decision is expected in the coming months.